Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial
Yixian Liu,1,2,* Xiaoyu Li,1,2,* Mengyu Zhang,1,2 Yuchun Men,1,2 Ying Wang,1,2 Xiaohong Zhu,1,2 Li Zheng1,2 1Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, People’s Republic of China; 2Clinical Trial Center, NMPA Key Laboratory for Clinical Research and Eval...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-01-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/effects-of-food-on-the-pharmacokinetics-and-safety-of-ha121-28-tablet--peer-reviewed-fulltext-article-DDDT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590430273798144 |
|---|---|
| author | Liu Y Li X Zhang M Men Y Wang Y Zhu X Zheng L |
| author_facet | Liu Y Li X Zhang M Men Y Wang Y Zhu X Zheng L |
| author_sort | Liu Y |
| collection | DOAJ |
| description | Yixian Liu,1,2,* Xiaoyu Li,1,2,* Mengyu Zhang,1,2 Yuchun Men,1,2 Ying Wang,1,2 Xiaohong Zhu,1,2 Li Zheng1,2 1Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, People’s Republic of China; 2Clinical Trial Center, NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, West China Hospital, Sichuan University, Chengdu, 610041, People’s Republic of China*These authors contributed equally to this workCorrespondence: Li Zheng, Cancer Center, West China Hospital, Sichuan University, No. 5 Telecom Road, Wuhou District, Chengdu, 610041, People’s Republic of China, Email zhengli@wchscu.cnPurpose: HA121-28, a novel multi-targeting tyrosine kinase inhibitor, has dual efficacy against tumor growth and neovascularization. The objectives of this study were to assess the effect of high-fat and high-calorie food on the pharmacokinetic (PK) profile and safety of HA121-28 tablet in healthy subjects.Patients and Methods: A single-dose, randomized, open-label, two-period, crossover-designed phase I clinical trial was conducted. Subjects received 200 mg HA121-28 in the fasted state or with high-fat and high-calorie breakfast. The effects of high-fat and high-calorie food on the PK profile and safety of HA121-28 were evaluated by using noncompartmental analysis and whole-process safety assessment.Results: Twenty subjects were successfully completed the trial. The geometric mean ratios (GMRs) for the peak concentration in plasma (Cmax), area under the curve from zero to the time point (AUClast), and area under the curve from zero to infinite (AUCinf) postprandially versus fasted were 108.45% (98.51% – 119.40%), 105.23% (100.25% – 110.47%), and 104.14% (97.41% – 111.34%), respectively. The majority of reported adverse events were graded as either level 1 or 2 in severity and recovered spontaneously without any interventions.Conclusion: The exposure of HA121-28 was not significantly affected by the high‐fat and high-calorie food. The clinical application of HA121-28 tablet can be recommended for use in both fasted and postprandial states.Keywords: HA121-28, ##Food effects, pharmacokinetics, safety, tyrosine kinase inhibitor |
| format | Article |
| id | doaj-art-d9452ef88bbf4e14a59ace3007981ab9 |
| institution | Kabale University |
| issn | 1177-8881 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj-art-d9452ef88bbf4e14a59ace3007981ab92025-01-23T18:50:32ZengDove Medical PressDrug Design, Development and Therapy1177-88812025-01-01Volume 1951552499545Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical TrialLiu YLi XZhang MMen YWang YZhu XZheng LYixian Liu,1,2,* Xiaoyu Li,1,2,* Mengyu Zhang,1,2 Yuchun Men,1,2 Ying Wang,1,2 Xiaohong Zhu,1,2 Li Zheng1,2 1Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, People’s Republic of China; 2Clinical Trial Center, NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, West China Hospital, Sichuan University, Chengdu, 610041, People’s Republic of China*These authors contributed equally to this workCorrespondence: Li Zheng, Cancer Center, West China Hospital, Sichuan University, No. 5 Telecom Road, Wuhou District, Chengdu, 610041, People’s Republic of China, Email zhengli@wchscu.cnPurpose: HA121-28, a novel multi-targeting tyrosine kinase inhibitor, has dual efficacy against tumor growth and neovascularization. The objectives of this study were to assess the effect of high-fat and high-calorie food on the pharmacokinetic (PK) profile and safety of HA121-28 tablet in healthy subjects.Patients and Methods: A single-dose, randomized, open-label, two-period, crossover-designed phase I clinical trial was conducted. Subjects received 200 mg HA121-28 in the fasted state or with high-fat and high-calorie breakfast. The effects of high-fat and high-calorie food on the PK profile and safety of HA121-28 were evaluated by using noncompartmental analysis and whole-process safety assessment.Results: Twenty subjects were successfully completed the trial. The geometric mean ratios (GMRs) for the peak concentration in plasma (Cmax), area under the curve from zero to the time point (AUClast), and area under the curve from zero to infinite (AUCinf) postprandially versus fasted were 108.45% (98.51% – 119.40%), 105.23% (100.25% – 110.47%), and 104.14% (97.41% – 111.34%), respectively. The majority of reported adverse events were graded as either level 1 or 2 in severity and recovered spontaneously without any interventions.Conclusion: The exposure of HA121-28 was not significantly affected by the high‐fat and high-calorie food. The clinical application of HA121-28 tablet can be recommended for use in both fasted and postprandial states.Keywords: HA121-28, ##Food effects, pharmacokinetics, safety, tyrosine kinase inhibitorhttps://www.dovepress.com/effects-of-food-on-the-pharmacokinetics-and-safety-of-ha121-28-tablet--peer-reviewed-fulltext-article-DDDTha121-28food effectspharmacokineticssafetytyrosine kinase inhibitor |
| spellingShingle | Liu Y Li X Zhang M Men Y Wang Y Zhu X Zheng L Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial Drug Design, Development and Therapy ha121-28 food effects pharmacokinetics safety tyrosine kinase inhibitor |
| title | Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial |
| title_full | Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial |
| title_fullStr | Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial |
| title_full_unstemmed | Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial |
| title_short | Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial |
| title_sort | effects of food on the pharmacokinetics and safety of ha121 28 tablet a novel multi targeting tyrosine kinase inhibitor in healthy chinese subjects a phase i clinical trial |
| topic | ha121-28 food effects pharmacokinetics safety tyrosine kinase inhibitor |
| url | https://www.dovepress.com/effects-of-food-on-the-pharmacokinetics-and-safety-of-ha121-28-tablet--peer-reviewed-fulltext-article-DDDT |
| work_keys_str_mv | AT liuy effectsoffoodonthepharmacokineticsandsafetyofha12128tabletanovelmultitargetingtyrosinekinaseinhibitorinhealthychinesesubjectsaphaseiclinicaltrial AT lix effectsoffoodonthepharmacokineticsandsafetyofha12128tabletanovelmultitargetingtyrosinekinaseinhibitorinhealthychinesesubjectsaphaseiclinicaltrial AT zhangm effectsoffoodonthepharmacokineticsandsafetyofha12128tabletanovelmultitargetingtyrosinekinaseinhibitorinhealthychinesesubjectsaphaseiclinicaltrial AT meny effectsoffoodonthepharmacokineticsandsafetyofha12128tabletanovelmultitargetingtyrosinekinaseinhibitorinhealthychinesesubjectsaphaseiclinicaltrial AT wangy effectsoffoodonthepharmacokineticsandsafetyofha12128tabletanovelmultitargetingtyrosinekinaseinhibitorinhealthychinesesubjectsaphaseiclinicaltrial AT zhux effectsoffoodonthepharmacokineticsandsafetyofha12128tabletanovelmultitargetingtyrosinekinaseinhibitorinhealthychinesesubjectsaphaseiclinicaltrial AT zhengl effectsoffoodonthepharmacokineticsandsafetyofha12128tabletanovelmultitargetingtyrosinekinaseinhibitorinhealthychinesesubjectsaphaseiclinicaltrial |